{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:11:09Z","timestamp":1789009869539,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["107592"],"award-info":[{"award-number":["107592"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["110515"],"award-info":[{"award-number":["110515"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who benefitted from treatment intensification. A previously developed neural network was employed for iPET analysis to identify the highest pathological FDG uptake (max-SUV<jats:sub>AI<\/jats:sub>) and the mean FDG uptake of all lymphoma manifestations (mean-SUV<jats:sub>AI<\/jats:sub>). High mean-SUV<jats:sub>AI<\/jats:sub> uptake was determined separately for iPET-positive and iPET-negative patients. The endpoint was time-to-progression (TTP). There was a significant interaction of additional rituximab and mean-SUV<jats:sub>AI<\/jats:sub> in the iPET-negative group (HR\u2009=\u20090.6, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Patients with high mean-SUV<jats:sub>AI<\/jats:sub> had significantly prolonged TTP when treated with 6xR-CHOP\u2009+\u20092\u2009R (not reached versus 52 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), whereas max-SUV<jats:sub>manual<\/jats:sub> failed to show an impact of additional rituximab. In the iPET-positive group, patients with high mean-SUV<jats:sub>AI<\/jats:sub> had a significantly longer TTP with (R-)CHOP than with the Burkitt protocol (14 versus 4 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Comprehensive iPET evaluation may provide new prognosticators in aggressive lymphoma. Additional application of rituximab was associated with prolonged TTP in iPET-negative patients with high mean-SUV<jats:sub>AI<\/jats:sub>. Comprehensive iPET interpretation could identify high-risk patients who benefit from study-specific interventions.<\/jats:p>","DOI":"10.1038\/s41375-022-01713-y","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T19:02:50Z","timestamp":1665774170000},"page":"2845-2852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-7701","authenticated-orcid":false,"given":"Robert","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rischpler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sandach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weckesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-3873","authenticated-orcid":false,"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-9472","authenticated-orcid":false,"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"1713_CR1","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"1713_CR2","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N. Engl J Med. 2016;374:2419\u201329.","journal-title":"N. Engl J Med"},{"key":"1713_CR3","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography\u2013guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024\u201334.","journal-title":"J Clin Oncol"},{"key":"1713_CR4","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","volume":"48","author":"C Lin","year":"2007","unstructured":"Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626\u201332.","journal-title":"J Nucl Med"},{"key":"1713_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50:1257\u201360.","journal-title":"Leuk Lymphoma"},{"key":"1713_CR6","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: The lugano classification. J Clin Oncol. 2014;32:3059\u201367.","journal-title":"J Clin Oncol"},{"key":"1713_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/hon.2697","volume":"38","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Rekowski J, M\u00fcller SP, Hertenstein B, Franzius C, Ganser A, et al. Baseline and interim PET\u2010based outcome prediction in peripheral T\u2010cell lymphoma: A subgroup analysis of the PETAL trial. Hematol Oncol. 2020;38:244\u201356.","journal-title":"Hematol Oncol"},{"key":"1713_CR8","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1080\/10428194.2020.1713319","volume":"61","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Rekowski J, Reinke S, M\u00fcller SP, H\u00fcttmann A, Klapper W, et al. Metabolic tumor volume, cancer cell fraction, and prognosis\u2014the case of T-cell\/histiocyte-rich large B-cell lymphoma. Leuk Lymphoma. 2020;61:1372\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1713_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","volume":"124","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, H\u00fcttmann A, M\u00fcller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25\u201336.","journal-title":"Eur J Cancer"},{"key":"1713_CR10","doi-asserted-by":"crossref","unstructured":"Weber M, Kersting D, Umutlu L, Sch\u00e4fers M, Rischpler C, Fendler WP, et al. Just another \u201cClever Hans\u201d? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. Eur J Nucl Med Mol Imaging. 2021;48:3141\u201350.","DOI":"10.1007\/s00259-021-05270-x"},{"key":"1713_CR11","first-page":"jnumed.120.2424","volume":"57","author":"N Capobianco","year":"2020","unstructured":"Capobianco N, Meignan MA, Cottereau A-S, Vercellino L, Sibille L, Spottiswoode B, et al. Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma. J Nucl Med. 2020;57:jnumed.120.242412.","journal-title":"J Nucl Med"},{"key":"1713_CR12","doi-asserted-by":"crossref","unstructured":"Sibille L, Seifert R, Avramovic N, Vehren T, Spottiswoode B, Zuehlsdorff S, et al. 18 F-FDG PET\/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks. Radiology. 2020;294:445\u201352.","DOI":"10.1148\/radiol.2019191114"},{"key":"1713_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-018-3578-0","volume":"98","author":"A H\u00fcttmann","year":"2019","unstructured":"H\u00fcttmann A, Rekowski J, M\u00fcller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the \u201cPositron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas\u201d (PETAL) trial. Ann Hematol Ann Hematol. 2019;98:897\u2013907.","journal-title":"Ann Hematol Ann Hematol"},{"key":"1713_CR14","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria; 2021. page http:\/\/www.R-project.org\/."},{"key":"1713_CR15","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trn\u011bn\u00fd M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529\u201337.","journal-title":"J Clin Oncol"},{"key":"1713_CR16","doi-asserted-by":"crossref","unstructured":"Marofi F, Rahman HS, Achmad MH, Sergeevna KN, Suksatan W, Abdelbasset WK, et al. A deep insight into CAR-T cell therapy in non-Hodgkin lymphoma: application, opportunities, and future directions. Front Immunol. 2021;12:681984.","DOI":"10.3389\/fimmu.2021.681984"},{"key":"1713_CR17","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"1713_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","volume":"8","author":"F Lordick","year":"2007","unstructured":"Lordick F, Ott K, Krause B-J, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797\u2013805.","journal-title":"Lancet Oncol"},{"key":"1713_CR19","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/JCO.20.02573","volume":"39","author":"S Alig","year":"2021","unstructured":"Alig S, Macaulay CW, Kurtz DM, D\u00fchrsen U, H\u00fcttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:2605\u201316.","journal-title":"J Clin Oncol"},{"key":"1713_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s00259-020-05080-7","volume":"48","author":"P Blanc-Durand","year":"2021","unstructured":"Blanc-Durand P, J\u00e9gou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bod\u00e9r\u00e9 F, et al. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET\/CT for total metabolic tumour volume prediction using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2021;48:1362\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1713_CR21","doi-asserted-by":"crossref","unstructured":"Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, D\u00fchrsen U, et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International metabolic prognostic index. J Clin Oncol. 2022;40:2352\u201360.","DOI":"10.1200\/JCO.21.02063"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01713-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:06:36Z","timestamp":1669795596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01713-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01713-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DK received a research grant from Pfizer outside of the submitted work. CR recieved a research grant from Pfizer, reports consultancy for Pfizer and Adacap, and speaker honoraria from Adacap, Alnylam, BTG, GE Healthcare, Pfizer, and Siemens Healthineers, all outside the submitted work. HCR received consulting and lecture fees from Abbvie, AstraZeneca, Vertex, Roche, and Merck. HCR received research funding from Gilead Pharmaceuticals and AstraZeneca. HCR is a co-founder of CDL Therapeutics GmbH. KH received personal fees from BTG, Bayer, Sofie Biosciences, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Aktis, Oncology, Pharma15 as well as non-financial support from ABX and grants from BTG. UD chairs data and safety monitoring boards of studies performed by Amgen and CPT Cellex Patient Treatment. WPF reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speakers bureau), Calyx (consultant), Bayer (consultant, speakers bureau), and Parexel (image review) outside of the submitted work. RS has received research support from the Else Kr\u00f6ner-Fresenius-Stiftung and Boehringer Ingelheim Fonds. The University Hospital M\u00fcnster, Department of Nuclear Medicine received a research grant from Siemens Healthineers, which supported the execution of the study. All other authors declare no conflict of interest with respect to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}